IART

+ Watchlist + Portfolio

Integra LifeSciences Holdings Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $17.24
52-Week Range: $8.70 – $20.49
Market Cap: $1.29B
P/E (TTM): —
EPS (TTM): -0.09
Dividend Yield: —

Advanced Metrics

Price/Book: 1.24
PEG Ratio: 0.67
Return on Equity: -0.70%
Return on Assets: 2.83%
Gross Margin: 56.87%
Operating Margin: 9.62%
Profit Margin: -0.44%
Current Ratio: 3.60
Debt/Equity: 1.96
Total Debt: $2.05B
Free Cash Flow: $94.40M
Revenue Growth: 0.80%
Earnings Growth: —
Enterprise Value: $3.12B

IART Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$1.56B	$1.54B	$1.61B	$1.64B
Cost of Revenue	$587.36M	$656.84M	$728.47M	$803.63M
Gross Profit	$970.31M	$884.74M	$882.06M	$831.62M
Research & Development	$101.19M	$104.19M	$115.38M	$98.97M
Selling, General & Admin	$616.32M	$656.64M	$716.98M	$699.70M
Operating Expenses	$731.39M	$773.21M	$853.65M	$813.63M
Operating Income	$238.92M	$111.53M	$28.41M	$18.00M
EBITDA	$381.79M	$255.96M	$193.29M	-$325.42M
Pretax Income	$213.89M	$81.07M	-$18.24M	-$563.50M
Income Tax	$33.34M	$13.33M	-$11.29M	-$47.03M
Net Income	$180.55M	$67.74M	-$6.94M	-$516.47M
Diluted EPS	2.16	0.84	-0.09	-6.74
Diluted Shares	83.59M	80.34M	77.16M	77.89M

IART Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$456.66M	$276.40M	$246.38M	$235.05M
Receivables	$263.46M	$259.33M	$272.37M	$278.85M
Inventory	$324.58M	$389.61M	$429.09M	$492.74M
Current Assets	$1.16B	$1.06B	$1.08B	$1.16B
Total Assets	$3.89B	$3.78B	$4.04B	$3.60B
Current Liabilities	$320.91M	$306.98M	$922.13M	$455.98M
Long-Term Debt	$1.41B	$1.49B	$1.20B	$1.73B
Total Debt	$1.62B	$1.68B	$1.98B	$2.03B
Total Liabilities	$2.09B	$2.19B	$2.49B	$2.56B
Retained Earnings	$879.12M	$946.86M	$939.91M	$423.44M
Shareholders' Equity	$1.80B	$1.59B	$1.55B	$1.04B
Working Capital	$840.59M	$751.06M	$159.56M	$703.56M
Net Debt	$986.65M	$1.22B	$1.56B	$1.62B

IART Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$264.47M	$139.96M	$129.38M	$50.38M
Capital Expenditure	-$47.09M	-$66.86M	-$114.37M	-$95.64M
Free Cash Flow	$217.38M	$73.09M	$15.01M	-$45.25M
Depreciation & Amortisation	$118.30M	$123.51M	$140.89M	$151.83M
Stock-Based Compensation	$27.73M	$20.14M	$24.38M	$18.58M
Investing Cash Flow	-$58.58M	-$94.18M	-$390.81M	-$108.06M
Financing Cash Flow	-$251.95M	-$229.93M	$237.86M	$28.34M
Share Repurchases	-$125.00M	-$275.00M	-$52.47M	-$221.00K
Net Change in Cash	-$46.06M	-$184.15M	-$23.56M	-$29.34M

IART Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$382.65M	$415.61M	$402.06M	$434.93M	$391.92M
Cost of Revenue	$188.22M	$206.27M	$195.07M	$214.06M	$174.94M
Gross Profit	$194.43M	$209.33M	$206.99M	$220.87M	$216.98M
Research & Development	$24.73M	$27.00M	$22.46M	$24.79M	$23.50M
Selling, General & Admin	$181.50M	$179.89M	$169.05M	$169.27M	$178.24M
Operating Expenses	$209.93M	$210.64M	$195.23M	$197.82M	$205.51M
Operating Income	-$15.50M	-$1.31M	$11.76M	$23.04M	$11.47M
EBITDA	$25.97M	-$472.22M	$54.42M	$66.41M	$58.49M
Pretax Income	-$30.04M	-$530.95M	-$6.82M	$4.31M	-$2.41M
Income Tax	-$4.74M	-$46.88M	-$1.42M	$6.01M	$2.21M
Net Income	-$25.29M	-$484.07M	-$5.40M	-$1.70M	-$4.62M
Diluted EPS	-0.33	-6.31	-0.07	-0.02	-0.06
Diluted Shares	77.71M	77.92M	77.20M	77.89M	76.95M

IART Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$239.10M	$217.91M	$232.19M	$235.05M	$236.81M
Receivables	$252.45M	$284.51M	$262.16M	$278.85M	$264.41M
Inventory	$445.42M	$465.13M	$489.11M	$492.74M	$495.04M
Current Assets	$1.11B	$1.14B	$1.14B	$1.16B	$1.17B
Total Assets	$4.05B	$3.67B	$3.65B	$3.60B	$3.58B
Current Liabilities	$918.45M	$929.81M	$364.05M	$455.98M	$346.85M
Long-Term Debt	$1.23B	$1.23B	$1.79B	$1.73B	$1.83B
Total Debt	$2.02B	$2.01B	$2.01B	$2.03B	$2.04B
Total Liabilities	$2.53B	$2.63B	$2.61B	$2.56B	$2.54B
Retained Earnings	$914.62M	$430.55M	$425.14M	$423.44M	$418.82M
Shareholders' Equity	$1.52B	$1.04B	$1.04B	$1.04B	$1.04B
Working Capital	$188.79M	$213.02M	$779.53M	$703.56M	$825.17M
Net Debt	$1.60B	$1.62B	$1.60B	$1.62B	$1.63B

IART Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$11.26M	$8.92M	$40.91M	$11.82M	$9.80M
Capital Expenditure	-$28.92M	-$20.15M	-$15.16M	-$31.42M	-$14.85M
Free Cash Flow	-$40.18M	-$11.23M	$25.75M	-$19.60M	-$5.04M
Depreciation & Amortisation	$37.19M	$37.69M	$38.52M	$38.43M	$38.43M
Stock-Based Compensation	$1.87M	$5.29M	$5.58M	$5.84M	$5.17M
Investing Cash Flow	-$35.92M	-$21.65M	-$15.59M	-$34.91M	-$14.85M
Financing Cash Flow	$35.38M	-$21.14M	-$10.24M	$24.34M	$8.30M
Share Repurchases	—	—	$0.00	$0.00	—
Net Change in Cash	-$11.80M	-$33.87M	$15.07M	$1.25M	$3.25M

Market Snapshot

About

Integra LifeSciences Holdings Corp. is a global medical technology company that develops, manufactures, and markets medical devices and implants for neurosurgery, orthopedics, and reconstructive surgery applications. The company's product portfolio includes neurosurgical instruments, tissue ablation equipment, wound reconstruction products, and orthopedic implants used by surgeons worldwide. Integra operates through two main business segments: Codman Specialty Surgical (neurosurgical products) and Tissue Technologies (regenerative medicine and wound care). The company serves hospitals, surgery centers, and healthcare providers across more than 100 countries. Integra combines organic innovation with strategic acquisitions to expand its product offerings and market presence in the medical device industry.